Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Respir Med. 2019 Apr 17;152:89–96. doi: 10.1016/j.rmed.2019.04.005

Fig. 3.

Fig. 3.

Relationships between serum CXCL11 levels and pulmonary function measurements and dyspnea scores.

A) CXCL11 levels were compared between sarcoidosis subjects dichotomized into two groups based on normal or abnormal spirometry and diffusing capacity measurements using a threshold of 80% predicted. B&C) Correlations between CXCL11 and both FVC %pred and FEV1 %pred. D) Correlations between CXCL11 and dyspnea scores where increasing score reflects more dyspnea. Data are displayed as A) log10 transformation of serum CXCL11 (individual levels denoted by grey open circles), bars representing mean values with 95% confidence intervals, and the lower limits of assay detection denoted by the dashed line; statistical significance was determined using the Wilcoxon rank-sum test (***p< 0.001 *p <0.05). For B-D), Spearman correlations of log10 transformation of CXCL11 levels (and Dyspnea scores) where indicated (*p <0.05, †p = 0.058).

Abbreviations: FEV1 %pred = Forced Expiratory Volume in 1 Second percent predicted, FVC %pred = Forced Vital Capacity percent predicted, DLCO %pred = Diffusing Capacity for Carbon Monoxide percent predicted.